FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2566185963> ?p ?o ?g. }

• W2566185963 abstract "Introduction: The increasing incidence of pancreatic cancer is associated with a rising prevalence of obesity, a documented risk factor for the disease. Obesity harbors a systemic chronic inflammatory disorder characterized by increased production and secretion of pro-inflammatory adipokines leptin, TNF-α, and IL-6; while exhibiting a decrease in the anti-inflammatory adipokine; adiponectin. Dysregulation of these factors is thought to be a key mechanism of obesity associated cancers, contributing to increased activation of mitogenic pathways including PI3K and MAPK. Adiponectin represents an important negative regulator of leptin, TNF-α and IL-6. We previously demonstrated that adiponectin inhibits pancreatic cancer proliferation and tumor growth, however, the molecular mechanisms by which adiponectin regulates these processes are unknown. We hypothesize that Adiponectin Receptor (AdipoR) agonists elicit anti-tumor effects through suppression of RAS-MAPK mediated pathways and its downstream signaling components in pancreatic cancer progression. Experimental Procedures: The anti-tumor effects of AdipoRon, a novel small molecule agonist of the AdipoR, were assessed in vitro on human (MiaPaca-2 and Panc-1) and murine (P-4313 and K8484) pancreatic cancer cell lines. Cells were treated with AdipoRon in a dose-dependent manner and then assayed for cellular proliferation, apoptosis, colony formation and anchorage-independent growth. The effect of AdipoRon on activation of key RAS-MAPK signaling regulators was investigated by immunoblot analysis. To determine whether AdipoRon could inhibit the effects of obesity associated pro-tumorigenic cytokines, human and mouse pancreatic cancer cells were exposed to plasma collected from obese mice or specifically with recombinant cytokines. To determine whether AdipoRon could inhibit tumor growth in vivo, mice were orthotopically injected in the pancreas with the murine KrasG12D mutant P-4313 cell line. Tumors were allowed to establish for two weeks and treated with either vehicle or AdipoRon. Tumor size and number of Ki67 positive cells were assessed. Results: Compared to vehicle treatment, in vitro assessment confirmed that AdipoRon was highly effective at inhibiting cell proliferation, increasing apoptosis and preventing colony formation for all pancreatic cell lines tested. Anchorage independent growth was drastically reduced for both Panc1 (3.8 fold) and MiaPaca-2 (5.1 fold) cell lines in the presence of AdipoRon. Treatment of both murine and human pancreatic cancer cell lines with AdipoRon caused a significant dose dependent decrease in pSTAT3, pERK1, and pERK2 with a simultaneous increase in pAMPK. Importantly, AdipoRon completely antagonized the stimulatory effects of obese plasma or recombinant IL-6 on the activation of pSTAT3. Administration of AdipoRon to P-4313 orthotopic pancreatic tumor bearing mice resulted in four fold decrease in tumor size and a 50% reduction in tumor cell proliferation. Conclusions: AdipoRon, an adiponectin receptor agonist, suppresses KRAS signaling mediators ERK and STAT3 while simultaneously increasing AMPK resulting in inhibition of pancreatic cancer proliferation and tumor growth. Targeting of adiponectin receptors can provide a viable therapeutic strategy for the treatment of pancreatic cancer. Citation Format: Fanuel Messaggio, Alisha M. Mendonsa, Jason A. Castellanos, Casey Roberts, Nagaraj S. Nagathihalli, Nipun B. Merchant, Lee D. Gorden, Michael N. VanSaun.{Authors}. AdipoRon suppresses ERK and STAT3 to inhibit pancreatic cancer growth. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2016 May 12-15; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2016;76(24 Suppl):Abstract nr A46." @default.
• W2566185963 created "2017-01-06" @default.
• W2566185963 creator A5016606073 @default.
• W2566185963 creator A5034445995 @default.
• W2566185963 creator A5036334812 @default.
• W2566185963 creator A5036458814 @default.
• W2566185963 creator A5048658282 @default.
• W2566185963 creator A5074108035 @default.
• W2566185963 creator A5077311762 @default.
• W2566185963 creator A5089892248 @default.
• W2566185963 date "2016-12-14" @default.
• W2566185963 modified "2023-09-27" @default.
• W2566185963 title "Abstract A46: AdipoRon suppresses ERK and STAT3 to inhibit pancreatic cancer growth" @default.
• W2566185963 doi "https://doi.org/10.1158/1538-7445.panca16-a46" @default.
• W2566185963 hasPublicationYear "2016" @default.
• W2566185963 type Work @default.
• W2566185963 sameAs 2566185963 @default.
• W2566185963 citedByCount "0" @default.
• W2566185963 crossrefType "proceedings-article" @default.
• W2566185963 hasAuthorship W2566185963A5016606073 @default.
• W2566185963 hasAuthorship W2566185963A5034445995 @default.
• W2566185963 hasAuthorship W2566185963A5036334812 @default.
• W2566185963 hasAuthorship W2566185963A5036458814 @default.
• W2566185963 hasAuthorship W2566185963A5048658282 @default.
• W2566185963 hasAuthorship W2566185963A5074108035 @default.
• W2566185963 hasAuthorship W2566185963A5077311762 @default.
• W2566185963 hasAuthorship W2566185963A5089892248 @default.
• W2566185963 hasConcept C121608353 @default.
• W2566185963 hasConcept C126322002 @default.
• W2566185963 hasConcept C134018914 @default.
• W2566185963 hasConcept C194832188 @default.
• W2566185963 hasConcept C2776782570 @default.
• W2566185963 hasConcept C2777391703 @default.
• W2566185963 hasConcept C2779183219 @default.
• W2566185963 hasConcept C2780210213 @default.
• W2566185963 hasConcept C2780613262 @default.
• W2566185963 hasConcept C502942594 @default.
• W2566185963 hasConcept C511355011 @default.
• W2566185963 hasConcept C555293320 @default.
• W2566185963 hasConcept C57074206 @default.
• W2566185963 hasConcept C62478195 @default.
• W2566185963 hasConcept C71924100 @default.
• W2566185963 hasConcept C86554907 @default.
• W2566185963 hasConcept C86803240 @default.
• W2566185963 hasConcept C95444343 @default.
• W2566185963 hasConceptScore W2566185963C121608353 @default.
• W2566185963 hasConceptScore W2566185963C126322002 @default.
• W2566185963 hasConceptScore W2566185963C134018914 @default.
• W2566185963 hasConceptScore W2566185963C194832188 @default.
• W2566185963 hasConceptScore W2566185963C2776782570 @default.
• W2566185963 hasConceptScore W2566185963C2777391703 @default.
• W2566185963 hasConceptScore W2566185963C2779183219 @default.
• W2566185963 hasConceptScore W2566185963C2780210213 @default.
• W2566185963 hasConceptScore W2566185963C2780613262 @default.
• W2566185963 hasConceptScore W2566185963C502942594 @default.
• W2566185963 hasConceptScore W2566185963C511355011 @default.
• W2566185963 hasConceptScore W2566185963C555293320 @default.
• W2566185963 hasConceptScore W2566185963C57074206 @default.
• W2566185963 hasConceptScore W2566185963C62478195 @default.
• W2566185963 hasConceptScore W2566185963C71924100 @default.
• W2566185963 hasConceptScore W2566185963C86554907 @default.
• W2566185963 hasConceptScore W2566185963C86803240 @default.
• W2566185963 hasConceptScore W2566185963C95444343 @default.
• W2566185963 hasLocation W25661859631 @default.
• W2566185963 hasOpenAccess W2566185963 @default.
• W2566185963 hasPrimaryLocation W25661859631 @default.
• W2566185963 hasRelatedWork W11702054 @default.
• W2566185963 hasRelatedWork W14997083 @default.
• W2566185963 hasRelatedWork W1837200 @default.
• W2566185963 hasRelatedWork W19185887 @default.
• W2566185963 hasRelatedWork W23268577 @default.
• W2566185963 hasRelatedWork W23296015 @default.
• W2566185963 hasRelatedWork W28790627 @default.
• W2566185963 hasRelatedWork W29497872 @default.
• W2566185963 hasRelatedWork W4914200 @default.
• W2566185963 hasRelatedWork W18138810 @default.
• W2566185963 isParatext "false" @default.
• W2566185963 isRetracted "false" @default.
• W2566185963 magId "2566185963" @default.
• W2566185963 workType "article" @default.